Oktober 2026
Erstellen Sie ein Konto, um Similarweb weiterhin zu nutzen
Lassen sie sich Website-Metriken, Keywords, Top-Marketing-Kanäle, Marktforschungs-Tools und mehr anzeigen.
Erstellen Sie Ihr kostenloses Kontoijbs.com
Globaler Rang
#443,056
69,522Geschätzte Daten von Similarweb anzeigen.
Überprüfen Sie die Metriken Ihrer Website öffentlich, indem Sie Ihr GA4 verbinden
Reflektieren Sie Ihren Erfolg
Überprüfen Sie die Traffic- und Engagement-Metriken Ihrer Website durch Verbinden mit Google Analytics
Absprungrate
47.17%
Verweildauer
2.13
Durchschnittliche Besuchsdauer
00:00:50
- Unternehmen
- - -
- Branche
- - -
Top 10 ijbs.com Wettbewerber
Die Top-10-Websites wie ijbs.com in Oktober 2026 sind in absteigender Reihenfolge nach ihrer Affinität zu ijbs.com in Bezug auf den jeweiligen Schlüsselwörter-Traffic, das Zielgruppen-Targeting und entsprechende Marktüberschneidungen aufgeführt
Nature is the foremost international weekly scientific journal in the world and is the flagship journal for Nature Portfolio. It publishes the finest ...
- Unternehmen
- nature
Globaler Rang
#1,656
109Absprungrate
55.37%
Verweildauer
2.51
Durchschnittliche Besuchsdauer
00:03:10
Similarity-Score
100%indexingmethod_automated - Search Results - PubMed
- Unternehmen
- - -
- Branche
- - -
Globaler Rang
- -
Länderranking
- -
Kategorischer Rang
- -
Absprungrate
- -
Verweildauer
- -
Durchschnittliche Besuchsdauer
- -
Similarity-Score
97%sciencedirect is the world's leading source for scientific, technical, and medical research. explore journals, books and articles.
- Unternehmen
- ScienceDirect
Globaler Rang
#369
10Absprungrate
31.28%
Verweildauer
6.01
Durchschnittliche Besuchsdauer
00:07:55
Similarity-Score
96%providing access to millions of research articles and chapters from science, technology and medicine, and humanities and social sciences
- Unternehmen
- - -
- Branche
- - -
Globaler Rang
- -
Länderranking
- -
Kategorischer Rang
- -
Absprungrate
62.14%
Verweildauer
2.23
Durchschnittliche Besuchsdauer
00:03:01
Similarity-Score
92%Cerebrospinal fluid–venous fistula is an increasingly recognized cause of spontaneous intracranial hypotension.[1][1] The site of the leak is between the dural sleeve around a spinal nerve root and the surrounding foraminal veins. In appropriately investigated patients, transvenous embolization of the draining foraminal and paraspinal veins has been shown to be an effective way of treating the disease, with low periprocedural morbidity, improvement in symptoms and radiological appearances.[2][2] [Video 1][3] shows the technique employed in a typical case using Onyx (Medtronic, Minnesota, USA) to embolize a CSF–venous fistula at the right T10 neural foramen. Video 1 Video showing the technique for trans-venous embolization of a right T10 CSF-venous fistula for the treatment of spontaneous intracranial hypotension. The first section covers patient selection and work up, before then focusing on the technical aspects of navigating through the azygos system to the target foramen and completely occluding the pathway for CSF outflow. [1]: #ref-1 [2]: #ref-2 [3]: #F1
- Unternehmen
- - -
- Branche
- - -
Globaler Rang
- -
Länderranking
- -
Kategorischer Rang
- -
Absprungrate
29.01%
Verweildauer
2.13
Durchschnittliche Besuchsdauer
00:00:59
Similarity-Score
83%Radioimmunotherapy using 225Ac, a highly cytotoxic α-particle emitter, has potential for treating advanced breast cancer, especially human epidermal growth factor receptor 2 (HER2)–positive cases. We use a pretargeted radioimmunotherapy (PRIT) approach consisting of a 3-step intravenous regimen (step 1: bispecific anti-HER2/anti-DOTA antibody; step 2: clearing agent; step 3: 225Ac-radiolabeled Proteus DOTA, or [225Ac]Ac-Pr). Our goal was to establish curative 225Ac-PRIT with high therapeutic indices. Methods: The impact of [225Ac]Ac-Pr specific activity was evaluated in the BT-474 breast xenograft model. We tested the effects of [225Ac]Ac-Pr dosing during PRIT on tumor-targeting efficiency and tissue biodistribution. Using a 225Ac-PRIT regimen consisting of a ratio of 1.19 nmol of bispecific antibody to 0.60–0.66 nmol of [225Ac]Ac-Pr, we evaluated therapy in the BT-474 model and a patient-derived xenograft model. BT-474-tumor–bearing mice were treated with 1 or 2 cycles of 225Ac-PRIT (37 kBq/cycle) separated by 1 wk. A dose escalation study was performed on the BT-474 model to establish an absorbed radiation dose of approximately 40 Gy (relative biological effectiveness [RBE], 5) as a nephrotoxic dose, as no such histologic findings were observed in prior studies at the 20.7-Gy (RBE, 5) renal dose level. Results: In the BT-474 model, 100% (20/20) achieved complete responses and histologic cure in 17 of 20 (85%) of the treated animals. One-cycle and 2-cycle treatments were equally effective. Treatments were well tolerated, with no chronic radiation toxicity documented during necropsy at 175 d. Dosimetry estimates (RBE, 5) per 37 kBq administered for tumors and kidneys were 210 and 3.5 Gy, respectively. In the patient-derived xenograft model, a single 225Ac-PRIT treatment led to 60% (3/5) complete response and prolonged survival (>93 d) versus no treatment (30 d; P = 0.0185). Lastly, a 225Ac-PRIT regimen was identified that induces severe chronic nephrotoxicity (41.4
- Unternehmen
- - -
- Branche
- - -
Globaler Rang
- -
Länderranking
- -
Kategorischer Rang
- -
Absprungrate
56.36%
Verweildauer
2.04
Durchschnittliche Besuchsdauer
00:01:23
Similarity-Score
82%- Unternehmen
- - -
- Branche
- - -
Globaler Rang
- -
Länderranking
- -
Kategorischer Rang
- -
Absprungrate
67.86%
Verweildauer
1.47
Durchschnittliche Besuchsdauer
00:00:06
Similarity-Score
80%Discover and read the most cited articles from BMJ Quality & Safety published over the past two years.
- Unternehmen
- - -
- Branche
- - -
Globaler Rang
- -
Länderranking
- -
Kategorischer Rang
- -
Absprungrate
59.32%
Verweildauer
2.28
Durchschnittliche Besuchsdauer
00:01:19
Similarity-Score
79%Oncology On the Go With ASTCT Talks | Podcasts | CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.
- Unternehmen
- CancerNetwork
Globaler Rang
#361,747
43,867Absprungrate
45.98%
Verweildauer
1.59
Durchschnittliche Besuchsdauer
00:00:35
Similarity-Score
78%- Unternehmen
- - -
- Branche
- - -
Globaler Rang
#325,519
1,594Absprungrate
52.85%
Verweildauer
1.56
Durchschnittliche Besuchsdauer
00:00:48
Similarity-Score
77%ijbs.comDie Top-5-Wettbewerber in Oktober 2026 lauten: nature.com, pubmed.ncbi.nlm.nih.gov, sciencedirect.com, link.springer.com und mehr.
Laut Similarweb-Daten zu monatlichen Besuchen ist nature.com in Oktober 2026 der Top-Wettbewerber von ijbs.com. Die zweitähnlichste Website ist pubmed.ncbi.nlm.nih.gov, gefolgt von sciencedirect.com auf Platz 3.
link.springer.com ist die viertähnlichste Website zu ijbs.com, während jnis.bmj.com in Oktober 2026 den fünften Platz belegt.
Die weiteren fünf Wettbewerber in der Top-10-Liste sind jnm.snmjournals.org, n.neurology.org, qualitysafety.bmj.com, cancernetwork.com und contemporaryobgyn.net.